Shortage warning

TGA issues warning over ongoing shortages of an arthritis treatment The Therapeutic Goods Administration today (23 February) issued a warning that Bristol-Myers Squibb Australia Pty Ltd had notified them of continuing shortages affecting multiple presentations of abatacept (Orencia) products for the first half of the year. The shortages occurred because of manufacturing capacity constraints, supplier